{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:34:32Z","timestamp":1790289272638,"version":"4.1.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate (OM) combination in the treatment of seasonal allergic rhinitis (SAR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>The PubMed database and ClinicalTrials.gov were searched using the following terms: mometasone + olopatadine, GSP301, mometasone furoate, and olopatadine hydrochloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles published in English between January 1987 and August 2022 related to pharmacology, safety, and clinical trials were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In 2 phase II clinical trials, twice-daily (BID) and once-daily (QDay) intranasal OM demonstrated significant improvements in reflective total nasal symptom score (rTNSS) (BID P &lt; 0.001 and QDay P &lt; 0.001) and instantaneous total nasal symptom score (iTNSS) (BID P &lt; 0.001 and P &lt; 0.0001; QDay P &lt; 0.001 and P &lt; 0.0001). In 2 phase III clinical trials, BID OM showed significant improvements in rTNSS vs. placebo ( P &lt; 0.001), olopatadine monotherapy ( P = 0.03 and P = 0.003), and mometasone monotherapy ( P = 0.02 and P = 0.059).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>OM is indicated for treatment of SAR symptoms. Caution with use must be considered for certain high-risk patients, existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Due to its quick and sustained onset of action, OM may be an ideal agent for initial treatment of moderate-severe SAR for patients 12 years and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>OM significantly improves SAR symptoms and is a viable treatment option in short-term SAR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221124230","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T01:24:15Z","timestamp":1663637055000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Intranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-9527","authenticated-orcid":false,"given":"Lauren","family":"Lim","sequence":"first","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-8247","authenticated-orcid":false,"given":"Melissa","family":"Lipari","sequence":"additional","affiliation":[{"name":"Ambulatory Care, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, and Ascension St. John Hospital and Medical Center, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, and Ascension St. John Hospital, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"bibr1-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2010.31.3329"},{"key":"bibr2-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2386596"},{"key":"bibr3-10600280221124230","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2011.3.3.148"},{"key":"bibr4-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2007.02.031"},{"key":"bibr5-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.12.002"},{"key":"bibr6-10600280221124230","unstructured":"Ryalatris\n                      \u00ae\n                      (Olopatadine hydrochloride|mometasone furoatemonohydrate) [Package Insert] Columbus, OH: Glenmark Pharmaceuticals Inc, January 2022. Accessed August 8, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211746s000lbl.pdf."},{"key":"bibr7-10600280221124230","unstructured":"Patanase\n                      \u00ae\n                      (Olopatadine) Nasal Spray [Package Insert]. Fort Worth, TX: Alcon Laboratories, 2009. Accessed August 8, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021861s002lbl.pdf."},{"key":"bibr8-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.10.011"},{"key":"bibr9-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-015-3832-1"},{"key":"bibr10-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S98172"},{"key":"bibr11-10600280221124230","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.12.1426"},{"key":"bibr12-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033"},{"key":"bibr13-10600280221124230","first-page":"967073","volume":"2014","author":"van Galen KA","year":"2014","journal-title":"AIDS Res Treat"},{"key":"bibr14-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.3062"},{"key":"bibr15-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.01.005"},{"key":"bibr16-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61025-3"},{"key":"bibr17-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01808.x"},{"key":"bibr18-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.09.005"},{"key":"bibr19-10600280221124230","first-page":"761","volume":"2","author":"Berlucchi M","year":"2010","journal-title":"Therapeutics"},{"key":"bibr20-10600280221124230","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0015.4556"},{"key":"bibr21-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2018.39.4134"},{"key":"bibr22-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2018.39.4133"},{"key":"bibr23-10600280221124230","unstructured":"Nasonex (Mometasone) [Package Insert] Kenilworth \u00aeNJ: Schering Corporation, May 2010. Accessed August 8, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020762s038lbl.pdf."},{"key":"bibr24-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.11.007"},{"key":"bibr25-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.03.017"},{"key":"bibr26-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2019.40.4223"},{"key":"bibr27-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1111\/all.13133"},{"key":"bibr28-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00960-2"},{"key":"bibr29-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.007"},{"key":"bibr30-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1177\/0194599814562166"},{"key":"bibr31-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.630389"},{"key":"bibr32-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02543.x"},{"key":"bibr33-10600280221124230","doi-asserted-by":"publisher","DOI":"10.2500\/ajr.2007.21.2896"},{"key":"bibr34-10600280221124230","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-021-07085-w"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221124230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221124230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221124230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:06Z","timestamp":1777375026000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221124230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/10600280221124230"],"URL":"https:\/\/doi.org\/10.1177\/10600280221124230","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}